Notice of Proposed Rulemaking – OAR 333-023, "Prescription Drug Monitoring Program Reporting Requirements and User Access"
The Oregon Health Authority, Public Health Division is proposing permanent amendments to OAR chapter 333, division 23 related to the Prescription Drug Monitoring Program in order to implement HB 2257 (Oregon Laws 2019, chapter 583) and HB 2609 (Oregon Laws 2019, chapter 53) passed during the 2019 legislative session, and to clarify the intent of ORS 431A.855 regarding the State Medical Examiner designee access.
House Bill 2257 added Coordinated Care Organization (CCO) medical, pharmacy, and dental director to the list of authorized users, and added diagnosis code and reason for prescription to the list of fields collected in the PDMP. House Bill 2609 added dental directors to the list of authorized users to access the PDMP. These rules will allow the Oregon Health Authority to clarify the appropriate use for new user types and clarify when a pharmacist is required to report diagnosis code and reason for prescription to the PDMP.
You are invited to review and comment on the proposed rules. If you wish to present oral testimony, a public hearing will be held in Portland, Oregon at 800 NE Oregon St, Room 900, on November 19, 2019 at 9:00 a.m. You may also file written comments before 5:00 p.m. on November 22, 2019 by submitting them to the Public Health Division Rules Coordinator at the following address:
OHA, Public Health Division
Brittany Hall, Administrative Rules Coordinator
800 NE Oregon Street, Suite 930
Portland, Oregon 97232
E-mail comments to: email@example.com. You may also send comments by fax to (971) 673-1299.
Notice of Proposed Rulemaking Hearing
Statement of Need and Fiscal Impact
Full Text of Proposed Rules